Podcasts about phase ii

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Phase I vs. Phase II Metabolism⁠ from the Pharmacology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

Small Cap Breaking News You Can't Miss!Here's a quick rundown of the latest updates from standout small-cap companies making big moves today.ESGold (CSE: ESAU; OTCQB: ESAUF)Fully funded to finish construction at the Montauban Gold-Silver Project, with building on track for mid–Q4 2025 and production targeted for 2026. The plan aims to transition from development to cash flow while keeping exploration upside alive in Quebec and a JV opportunity in Colombia. Near-term catalysts include concentrate test results from both projects.Abcourt Mines (TSXV: ABI; OTCQB: ABMBF)At the Flordin Project in Québec, surface work extended gold mineralization 650+ meters west of the Cartwright area and outlined new parallel zones. A standout channel sample hit 9.5 g/t gold over 7.0 m, including 112.7 g/t over 0.5 m. Next up: drill targeting these newly exposed zones. Abcourt will present the update at the Munich Mining Conference, Oct. 3–4, 2025.American Eagle Gold (TSXV: AE)At the NAK copper-gold project (B.C.), the company intersected 73 m of 0.89% copper-equivalent within 277 m of 0.40% from surface—the first high-grade surface result in the North Zone. A new near-surface target inside the central stock also shows strong visible mineralization (assays pending). Three rigs turning, 20+ holes to go, and a cash balance of $36M supported by Teck and South32.Scottie Resources (TSXV: SCOT; OTCQB: SCTSF; FSE: SR80)More strong hits from the Blueberry Contact Zone, including 7.43 g/t gold over 18.75 m and 37.0 g/t over 2.85 m. The 25,000-m drill program is fully funded with

This week Dan Morehead joins the show to discuss the current state of markets & what's next throughout 2025 into 2026. We deep dive into how Dan built conviction in crypto as an asset class back in 2013, does the four year cycle still exist, crypto treasury vehicles, Dan's Solana thesis & more. Enjoy! -- Follow Dan: https://x.com/dan_pantera Follow Jason: https://x.com/JasonYanowitz Follow Empire: https://twitter.com/theempirepod -- Join the Empire Telegram: https://t.me/+CaCYvTOB4Eg1OWJh Start your day with crypto news, analysis and data from David Canellis. Subscribe to the Empire newsletter: https://blockworks.co/newsletter/empire?utm_source=podcasts -- Crypto-native institutions and developers demand institutional-grade infrastructure with regulatory clarity and full asset control. Blockdaemon's Earn Stack is a non-custodial platform combining high-performance staking rewards and seamless DeFi integration with no intermediate smart contract or vaults. Programmatically access leading Ethereum & Solana staking rewards, plus DeFi opportunities across lending protocols, DEXs, and AMMs. Book a Demo! -- Welcome to Get Real — Web3's first-ever campaign rewarding you for creating real-world value. Connect your devices to real-world apps on peaq and earn rewards for: Measuring noise pollution Providing compute Mapping the word And more Total prize pool: 5% of $PEAQ's initial supply. Get Real is relaunching soon — follow peaq on X and get ready. -- Mantle is pioneering ""Blockchain for Banking"" as a revolutionary new category that sits at the intersection of TradFi and web3. Key elements for Mantle as the ""Blockchain for Banking"": - Transactions posted to the blockchain - Compatibility with TradFi rails - Integrated DeFi features Mantle Network, the access layer — transforms Mantle Network into a purpose-built vertical platform — the blockchain for banking — that enables financial services on-chain. Mantle leads the establishment of Blockchain for Banking as the next frontier. Follow Mantle on X (@Mantle_Official) for the latest updates on Mantle as the 'Blockchain for Banking'. -- GEODNET is the world's largest RTK network, delivering real-time, centimeter-level precision for drones, robots, farmers, and first responders. Recognized by the U.S. Congress, this blockchain-powered network supports mission-critical applications across a wide range of industries. Discover how GEODNET is changing the world: [https://geodnet.com] -- Timestamps: (00:00) Introduction (02:44) Buying Bitcoin In The Early Days (07:11) Dan's Macro Outlook In 2025 (17:14) Ads (Blockdaemon, Peaq) (18:44) Does The Four Year Cycle Still Exist? (27:39) Phase II of The Bull Market (29:49) The Crypto IPO Window Is Open (32:44) Ads (Blockdaemon, Peaq) (34:13) Crypto Treasury Vehicles (40:30) The Solana Thesis: Why Pantera Owns $1bn+ Solana (42:45) Are Institutions Still Underallocated To Crypto? (46:33) Ads (Manttle, Goednet) (47:59) Launching Crypto's Longest Running Fund (55:07) Advice For Founders (57:50) Crypto's Biggest Opportunity In The Next 5 Years -- Disclaimer: Nothing said on Empire is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Santiago, Jason, and our guests may hold positions in the companies, funds, or projects discussed.

Ethan is a Baltimore-area investor who moved from offices and strip centers into strictly industrial after years of high capex and constant turnover in those assets. His 30,000 sf small-bay warehouse bought in 2013 for $2.15M has run nearly full for 12 years, needed little capex, and is now worth about $4.5M. Limited new supply of small bay, 3 percent annual rent bumps, and sticky tenants made it a cash cow. He sees big funds drifting down-market from big box to chase yield, but notes small-bay tenants are gritty and practical, so local owners who know the profile often have an edge.He has doubled down on industrial outdoor storage. A 16-acre site near Dover was bought for about $1.2M, improved with gravel, fencing, solar lights, cameras and an app-controlled gate, then run by a truck-parking operator. Pricing is about $175 per spot per month with daily and weekly options, modeled for roughly 180 stalls and now about 65 percent occupied, already covering the mortgage. He financed quickly via a line of credit then plans to refi after stabilization. A failed Phase I led to a clean Phase II, which unlocked the deal. He also owns two 5,000 sf warehouses with 1.5 acre yards leased to a pipe distributor, a contractor and a granite company, plus another IOS site across from Dover being turned into containerized self-storage. Strategy wise he avoids Baltimore City's higher taxes, favors Harford County and secondary markets near highways on the I-95 corridor, and targets IOS parcels of 3 to 5 acres or more where supply is scarce and demand is deep.--

Think you can crack the science first and worry about CMC when you "need it"? That's exactly how promising therapies die in regulatory limbo while patients keep waiting.Your breakthrough discovery means nothing if it's trapped in CMC chaos. While you're perfecting your molecular mechanism, competitors with inferior science but superior CMC strategy are racing past you to IND filing and ultimately, to patients.In this episode, I, David Brühlmann, your usual host, expose the dangerous delusion that's quietly bankrupting biotech startups: the belief that brilliant science automatically translates to successful drug development. Drawing from years of watching founders burn through millions because they treated CMC as an afterthought, I reveal why the smartest scientific minds often make the most catastrophic business decisions.Here's the hard truth you'll confront in this episode:The $50M Misconception: Why "CMC is just manufacturing" thinking destroys companies before they ever reach Phase II. While you're debating molecular targets, smart founders are building systematic CMC advantages that compress timelines and slash costs. The FDA doesn't care how elegant your science is if you can't demonstrate consistent, scalable manufacturing.The Brutal Mathematics of Delay: Systematic CMC approach: 10-12 months to IND, 85% hit timelines. "Figure it out later" approach: 15 months or more, and a much lower success rate. Every month you delay isn't just burning cash. If your therapy could help 10,000 patients annually, that's 833 people per month who don't get treatment because of preventable delays.Three Founder Myths That Kill Programs: The misconceptions about CMC being "basically just manufacturing," bringing in experts "when we need them," and CDMOs handling "the complicated stuff." Each myth leads to the same outcome: brilliant science trapped by business incompetence.Your Four-Action Emergency Protocol: Stop hoping CMC will work out. Start implementing systematic approaches. I give you four specific actions to execute this week, not someday when you're "ready," but right now while you can still prevent the crisis that kills 40% of biotech programs.The competitive reality: While you're listening to this episode, your biggest competitor just moved closer to IND filing. Maybe they completed process validation. Maybe they locked in analytical methods. The question isn't whether CMC matters. It's whether you'll master it before your competitors do.Next step:

We’re concluding our read of Zoraida Cordova’s novel, Convergence, part of Phase II of the High Republic project. This time, we talk about hoarding weapons of mass destruction, trusting your instincts, and real-world pop culture nods in the GFFA. For a list of Black-owned bookstores to order from, now and always, click here. You can […]

We’re continuing our read of Zoraida Cordova’s Convergence, the first adult novel in Phase II of the High Republic project. This time, we talk about life on the ground during wartime, shoddy planetary leadership, and arranged marriage tropes. For a list of Black-owned bookstores to order from, now and always, click here. You can subscribe […]

Oral therapies are projected to account for 25% of the anti-obesity medication market by 2030—but first returns have largely disappointed. This month, shares of both Eli Lilly and Viking Therapeutics took a hit as investors reacted negatively to highly anticipated Phase III and Phase II results for their respective candidates.While the 9.1% placebo-adjusted weight loss generated by Lilly's orforglipron over 72 weeks was an efficacy miss by most analyst accounts, tolerability tripped up oral VK2735's otherwise best-case efficacy scenario—10.9% weight loss after just 13 weeks. These murky results have left observers wondering, just how game-changing these pills will be and which ones will be most effective?In such a hot space, Lilly's and Viking's results—which follow Novo Nordisk's new drug application for an oral form of Wegovy in May—are only the tip of the iceberg. Stay tuned to BioSpace for further in-depth coverage of the space as we learn which investigational assets will make it across the regulatory finish line and which will join the weight-loss wasteland.

Collective Mining continues to define the shallow portion of the Apollo system with new drill results. Torq Resources and its Phase II drilling has discovered a new copper-gold porphyry area. GoldMining shares results of historic drill core re-assayed for antimony. Q2 Metals share positive met test work from Cisco. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Amapiano and 3Step grooves for the real late night lifers.

We’re reading Quest for the Hidden City, a High Republic middle-grade novel by George Mann. Join us as we discuss horror in Star Wars, Phase II worldbuilding, and the importance of a good copyeditor. For a list of Black-owned bookstores to order from, now and always, click here. You can subscribe to Audible and purchase […]

We’re discussing the second half of Path of Deceit, a YA novel by Tessa Gratton and Justina Ireland, and the first book in Phase II of The High Republic Project. Join us as we talk about the origins of the Nihil, the GFFA’s onsistently short memory, and an ending that absolutely blindsided us (in a […]

Dr Murali Ramachandra, CEO of Aurigene Oncology, talks to Anju Ghangurde about the tough biotech funding environment, promising pipeline assets including a CAR-T cell therapy in Phase II and ‘hybrid' manufacturing options, besides outcome-based reimbursement models. The promise of bispecifics and multispecifics in oncology, including Chinese biotech Akeso's PD-1/VEGF bispecific antibody, are some of the other topics he discussed.

Laurie Adami seemed to have it all.  She was the president of her company, at age 40, she had just had a son and still found time to lead an active lifestyle.  However, in 2003, her health took a turn for the worse.  She felt a lump in her abdomen, experienced frequent, lengthy sinus infections and chronic fatigue.  All this led to a diagnosis of Stage IV Follicular Non-Hodgkin Lymphoma.  After six unsuccessful treatment regimens, she achieved complete remission on the seventh try, completing a battle that ran twelve years.   When Laurie initially brought her symptoms to the attention of her family doctor, they were dismissed as, at worst, a hernia, and exhaustion due to her demanding schedule; but Laurie insisted there was nothing ordinary about her symptoms and changed doctors.   She saw a hernia specialist who ordered a CT scan, which revealed a mass the size of a small watermelon on her abdomen.  After a biopsy, Laurie learned she had Stage IV Follicular Non-Hodgkin Lymphoma.  At that time, she had no idea of the difficulty and length of the journey awaiting her.   The first of six treatments that failed to overcome her diagnosis was in 2006 and called R-CHOP.  It was a mix of Rituxan plus Cytoxan, Adriamyacin and Prednisone.   Next in 2008 was a clinical trial of Rituxan, along with an HDAC inhibitor.   In 2010, Laurie tried Bendamustin, a medication popular in Eastern Europe.   When that didn't work, later in the year, she went with Bexxar Radioimmunotherapy.   Of the first six regimens, Laurie had the most success with a pi3 kinase inhibitor called Zydelig.  For five and a half years ending in 2016, it shrunk the tumor without eliminating it. The tumor returned and for six months ending in September 2017, she tried infusions of Gazvya.   On July 16, 2018, her tumor was still around, but Laurie qualified for a Phase II clinical trial of Yescarta CAR-T therapy.  Some 29 days later, her lymphoma specialist informed her she was in full remission.   Laurie Adami has resumed an active lifestyle, and does plenty of traveling, most of it to public speaking engagements, as she serves as an advocate for the Leukemia & Lymphoma Society.   Additional Resources:   Support Group:   The Leukemia & Lymphoma Society  https://www.lls.org  

In this episode, we’re starting Phase II of the High Republic with Path of Deceit, a YA novel by Tessa Gratton and Justina Ireland. Join us as we discuss the state of the galaxy 400 years before the start of the Skywalker Saga, early connections to Phase I, and a new Force cult, the Path […]

Cam Coley returns to the show for his first update. After briefly reminding listeners of Cam's falconry situation, he and I talk about the progress that he has made with his new English setter pup.  Cam then tells us which one of the two options he was considering when we last spoke - going strait to flying wild quarry or opting to transition to Phase II of the Perfect Pigeon approach. We then discuss the use of bagged quarry in South African falconry. Cam had indicated that it was his intent to release his peregrine at the end of August and I ask Cam if he intends to follow through with that plan, and why he believes that doing so is in the best interests of the hawk. If, in fact, Cam does release his falcon, then it was his intent to replace it with either a passage lanneret or a musket black spar - he tells us which of the two options he has settled on. We then focus on some highlights of his season thus far. We conclude the episode with a description of Cam's most recent flight.  Thanks for listening to the Fat Bird, Ugly Dog Podcast - I hope you enjoy the episode.

Erik Wetterling, Founder and Editor of The Hedgeless Horseman website, joins us to review the value proposition that has his attention in the 3 pre-discovery gold and copper exploration companies, that have large Tier 1 drill targets and the potential for rapid upside moves if they make a compelling discovery and hit with the drill bit on current programs.     >> The companies we discussed in the interview are:   Rackla Metals Inc. (TSX-V: RAK) (OTC: RMETF) – On July 14th, 2025 Rackla Metals announced that drilling and had commenced at the BiTe zone on the Grad property NWT.  The Grad property was staked in July of 2024, and immediate prospecting defined strong gold mineralization at the base of the south facing cliff.  Further sampling in August identified significant sheeted veining hosted in the intrusive and that combined with the gold, bismuth and tellurium geochemistry made it clear that the Company had discovered a compelling Reduced Intrusion-related Gold Systems (RIRGS) occurrence that had never previously been identified or staked.   Inflection Resources Ltd. (CSE: AUCU) (OTCQB: AUCUF) – On July 21, 2025, Inflection Resources announced that it completed the acquisition of an 100% interest in a portfolio of copper-gold projects in the Northern Territory and New South Wales, Australia from subsidiaries of Newmont Corporation. This provides the company optionality on how to advance those properties. The main near-term value drivers will be when more assays get released from any of their four projects that JV option partner AngloGold Ashanti elected to advance to Phase II earn-in. The four Designated Projects are Duck Creek, Trangie, Crooked Creek and Nyngan.   Westward Gold Inc. (CSE: WG) (OTCQB: WGLIF) - On July 8, 2025, Westward Gold announced that drilling is underway at its flagship Toiyabe Hills Property in Lander County, Nevada. Over the next several months, Westward will be testing its Campfire Target Complex for the first time, with approximately 5,000 metres (~16,500 feet) of reverse-circulation (“RC”) drilling across this top-priority zone within the ~61 square-kilometer consolidated Property.     * In full disclosure, some companies mentioned by Erik in this interview, are positions held in his personal portfolio, and also may be site sponsors of The Hedgeless Horseman website at the time of this recording.   Click here to follow Erik's analysis over at The Hedgeless Horseman website

Former President John Mahama has officially cut the sod to begin Phase II of the Blekusu Coastal Protection Project. The ceremony took place at Agavedzi in the Ketu South constituency, where he was joined by local residents and traditional leaders.

SES has completed the acquisition of Intelsat. Planet Labs has announced a multi-year contract expansion with the Instituto Geográfico Agustín Codazzi (IGAC) in Colombia. Solestial has been selected by SpaceWERX for a Direct-to-Phase II contract in the amount of $1.2 million, and more. Remember to leave us a 5-star rating and review in your favorite podcast app. Be sure to follow T-Minus on LinkedIn and Instagram. T-Minus Guest Our guest today is Jacob Oakley,   Technical Director at SIXGEN and Space Lead for the DEFCON Aerospace Village.  You can connect with Jacob on LinkedIn, and learn more about the Aerospace Village on their website. Selected Reading SES Completes Acquisition of Intelsat, Creating Global Multi-Orbit Connectivity Powerhouse Planet Expands Multi-Year Contract with Instituto Geográfico Agustín Codazzi (IGAC), Providing Satellite Data and AI-Powered Analytics Feeds Across Colombia Solestial Awarded $1.2M by SpaceWERX for Space Solar Development SpaceX Plans Starship Program for In-Orbit Drug Research - Bloomberg ISS National Lab's Orbital Edge Accelerator Program Selects Six Startups NASA Sees Key Progress on Starlab Commercial Space Station Astronomers capture the birth of planets around a baby sun outside our solar system The handshake in orbit that made the International Space Station possible T-Minus Crew Survey Complete our annual audience survey before August 31. Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

Tehillah Niselow was in conversation with Rudi Dicks ,Head of the Project Management Office in the Private Office of the President about the details of this report and what South Africans can expect next.See omnystudio.com/listener for privacy information.

We weigh in on the recent DoJ Epstein memo and tape. Plus: Elon and Hitler. Hit the tip line: (646) 801-1129 | tips@trueanon.com Discover more episodes at podcast.trueanon.com

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 11, 2025. In this episode: Merck & Co's Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee's Phase II eczema win; and a look at India's wave of licensing. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-TJX4YBGD5JDSHGRUTLYHWO2JMU/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

This is Part 5 of the Phantoms Main Camp Recap! On deck, we welcome back Friend of the Show, Assistant GM Robbie Murden, and for the 1st time, we welcome Assistant GM and Director of European Scouting Adam Jonak! Robbie and Adam take us through some of this year's Phase II picks. Check it out!Send us a textMerch Store Official WebsiteFacebook This recording is the sole view of the members of the Dump & Chase Podcast. This is a non-commercial fan production. We are not affiliated with or compensated by the Youngstown Phantoms, the United States Hockey League, or any league, club, or team. © 2025 Dump & Chase Podcast. All Rights Reserved

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Beckley's psychedelic nasal spray, BPL-003, has successfully cleared Phase II trials for treatment-resistant depression, showing robust efficacy data. Analysts predict the asset could reach peak market sales of $1 billion. This paves the way for late-stage development and a proposed merger with atai life sciences. In other news, M&A activity saw a significant increase in June, with big pharmas like Eli Lilly, Sanofi, and Novartis making multiple deals. The FDA's decision to remove risk evaluation and mitigation strategies from approved CAR T cancer therapies has been well-received by the cell and gene therapy community. Additionally, Argenx has made a $1.5 billion acquisition of Unum Therapeutics' macrocyclic peptides, aimed at "undruggable" targets. Moderna, Merck, UroGen, and other companies received regulatory nods for various treatments in June. Evotec is hosting a webinar on preserving quality in the pharma industry amidst financial challenges on July 16. Job opportunities in the industry include positions at Biomarin Pharmaceutical Inc., Regeneron Pharmaceuticals, and AbbVie.

The U.S. Supreme Court closed out its session before breaking for summer on Friday, ruling that decisions around coverage of HIV PrEP drugs should be left up to the U.S. Preventive Services Task Force. The ruling thwarted a lawsuit brought by a group of insurance providers who challenged the Affordable Care Act's requirement that they cover preventive medicines, such as HIV drugs, recommended by the task force. The high court also determined that members of this task force can be removed at will by HHS Secretary Robert F. Kennedy Jr.Speaking of HHS committees from which members have been removed at will by Kennedy, the CDC's revamped Advisory Committee on Immunization Practices convened last week for its first meeting since the roster overhaul, where a vote on Merck's recently approved RSV-targeting monoclonal antibody Enflonsia and a discussion around the inclusion of preservative thimerosal in influenza vaccines was on the docket, but an expected vote on Moderna's mRNA-based RSV shot mRESVIA was not.Also dominating the headlines on Friday was the FDA's decision to remove the Risk Evaluation and Mitigation Strategies (REMS) program from the six approved CAR T therapies it was applied to. Analysts and patient groups lauded the move, which is expected to potentially double access to these life-saving therapies, saying it reflects “thoughtful consideration of real-world evidence” and “regulatory trust.”Willliam Blair noted that it could be a “positive signal” to companies developing CAR T therapies for autoimmune diseases, which now includes AbbVie. In an all-cash buyout on Monday, the Illinois-based pharma dropped $1.2 billion for Capstan Therapeutics and its in vivo edited CAR T therapy for B cell–mediated autoimmune diseases. M&A has been on an uptick of late, and private equity companies—such as those that snapped up bluebird bio—are also getting in on the game.Finally, after Lykos Therapeutics' high profile failure last summer, the psychedelics space is heating up once again. While a Phase III readout of Compass Pathways' psilocybin drug last week in treatment-resistant depression received a muted reaction from investors, the response to a Phase II readout for Beckley Psytech and atai Life Sciences' intranasal psychedelic was more positive.

Send us a textEpisode Description:In this episode, we sit down with pianist, singer, and producer Johanna Chukaree — better known as D Piano Girl — for an honest and uplifting conversation about creativity, healing, and purpose.Johanna shares her journey from early classical training and national music festival wins to a corporate career in engineering and HR — before finally stepping fully into her artistry. We get into the story behind her viral Savannah Grass cover, the emotional layers of her new single Forever, and how she blended Bollywood rhythms, Hindi lyrics, and Trinbagonian spirit to produce a deeply personal anthem.We talk about her process, her voice, and how music became a way to process life, raise her vibration, and reconnect with joy. From working out Phase II Pan Groove intros as a child in Woodbrook to making original music heard on major stations, Johanna opens up about learning to believe in herself — and how that belief shapes everything around her.

The aftermath of the attack on Callista's club leaves a bullet-ridden Lincoln scrambling to heal in time for Phase II of Dante's plan. Icepick is about to hear from a very unhappy employer. And through it all, the ticking time bomb that is Lincoln's family finally goes “boom.” Created by Scott Sigler and Rob Otto Written and performed by Scott Sigler Production Assistance by Allie Press Copyright 2025 by Empty Set Entertainment  Theme music is the song “They're Watching Me” by SUPERWEAPON. Family drama? Patch things up with a family website. Save 99% on a new dot-com with the GoDaddy Promo Code CJCFOSSIG3. Learn more about your ad choices. Visit megaphone.fm/adchoices

Topics covered in this episode: * Free-threaded Python no longer “experimental” as of Python 3.14* typed-ffmpeg pyleak * Optimizing Test Execution: Running live_server Tests Last with pytest* Extras Joke Watch on YouTube About the show Sponsored by PropelAuth: pythonbytes.fm/propelauth66 Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Brian #1: Free-threaded Python no longer “experimental” as of Python 3.14 “PEP 779 ("Criteria for supported status for free-threaded Python") has been accepted, which means free-threaded Python is now a supported build!” - Hugo van Kemenade PEP 779 – Criteria for supported status for free-threaded Python As noted in the discussion of PEP 779, “The Steering Council (SC) approves PEP 779, with the effect of removing the “experimental” tag from the free-threaded build of Python 3.14.” We are in Phase II then. “We are confident that the project is on the right path, and we appreciate the continued dedication from everyone working to make free-threading ready for broader adoption across the Python community.” “Keep in mind that any decision to transition to Phase III, with free-threading as the default or sole build of Python is still undecided, and dependent on many factors both within CPython itself and the community. We leave that decision for the future.” How long will all this take? According to Thomas Wouters, a few years, at least: “In other words: it'll be a few years at least. It can't happen before 3.16 (because we won't have Stable ABI support until 15) and may well take longer.” Michael #2: typed-ffmpeg typed-ffmpeg offers a modern, Pythonic interface to FFmpeg, providing extensive support for complex filters with detailed typing and documentation. Inspired by ffmpeg-python, this package enhances functionality by addressing common limitations, such as lack of IDE integration and comprehensive typing, while also introducing new features like JSON serialization of filter graphs and automatic FFmpeg validation. Features : Zero Dependencies: Built purely with the Python standard library, ensuring maximum compatibility and security. User-Friendly: Simplifies the construction of filter graphs with an intuitive Pythonic interface. Comprehensive FFmpeg Filter Support: Out-of-the-box support for most FFmpeg filters, with IDE auto-completion. Integrated Documentation: In-line docstrings provide immediate reference for filter usage, reducing the need to consult external documentation. Robust Typing: Offers static and dynamic type checking, enhancing code reliability and development experience. Filter Graph Serialization: Enables saving and reloading of filter graphs in JSON format for ease of use and repeatability. Graph Visualization: Leverages graphviz for visual representation, aiding in understanding and debugging. Validation and Auto-correction: Assists in identifying and fixing errors within filter graphs. Input and Output Options Support: Provide a more comprehensive interface for input and output options, including support for additional codecs and formats. Partial Evaluation: Enhance the flexibility of filter graphs by enabling partial evaluation, allowing for modular construction and reuse. Media File Analysis: Built-in support for analyzing media files using FFmpeg's ffprobe utility, providing detailed metadata extraction with both dictionary and dataclass interfaces. Michael #3: pyleak Detect leaked asyncio tasks, threads, and event loop blocking with stack trace in Python. Inspired by goleak. Use as context managers or function dectorators When using no_task_leaks, you get detailed stack trace information showing exactly where leaked tasks are executing and where they were created. Even has great examples and a pytest plugin. Brian #4: Optimizing Test Execution: Running live_server Tests Last with pytest Tim Kamanin “When working with Django applications, it's common to have a mix of fast unit tests and slower end-to-end (E2E) tests that use pytest's live_server fixture and browser automation tools like Playwright or Selenium. ” Tim is running E2E tests last for Faster feedback from quick tests To not tie up resources early in the test suite. He did this with custom “e2e” marker Implementing a pytest_collection_modifyitems hook function to look for tests using the live_server fixture, and for them automatically add the e2e marker to those tests move those tests to the end The reason for the marker is to be able to Just run e2e tests with -m e2e Avoid running them sometimes with -m "not e2e" Cool small writeup. The technique works for any system that has some tests that are slower or resource bound based on a particular fixture or set of fixtures. Extras Brian: Is Free-Threading Our Only Option? - Interesting discussion started by Eric Snow and recommended by John Hagen Free-threaded Python on GitHub Actions - How to add FT tests to your projects, by Hugo van Kemenade Michael: New course! LLM Building Blocks in Python Talk Python Deep Dives Complete: 600K Words of Talk Python Insights .folders on Linux Write up on XDG for Python devs. They keep pulling me back - ChatGPT Pro with o3-pro Python Bytes is the #1 Python news podcast and #17 of all tech news podcasts. Python 3.13.4, 3.12.11, 3.11.13, 3.10.18 and 3.9.23 are now available Python 3.13.5 is now available! Joke: Naming is hard

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.Jefferies predicts an increase in small tuck-in deals in the biotech industry as companies face challenges accessing capital. Companies and industry groups are offering solutions to mitigate the impact of Trump tariffs on rare disease, cell, and gene therapy. Pitchbook suggests a shift towards more sustainable investing in biotech VC firms. Gilead is gearing up to challenge J&J in the $20 billion multiple myeloma CAR-T market. PTP's generative AI is revolutionizing data summaries for biotech QC workflows. Sanofi recently acquired Blueprint for $9.5 billion, while BMS has committed up to $11 billion with Biontech. Lilly has signed a deal worth up to $870 million, and Regeneron is investing nearly $2 billion in a Chinese obesity drug. Merck's CEO is emphasizing diversity in operations following the defeat of an anti-DEI measure. Immuno-oncology drugs Keytruda and Opdivo may face scrutiny in the near future.In other news, Vigil Neuroscience's Trem2 antibody for a rare brain disease failed in a Phase II trial shortly after Sanofi's acquisition of the company. Analysts believe the results were not surprising and should not impact the deal. Lilly has signed a deal worth up to $870 million to develop a long-acting GLP-1 obesity drug, while the FDA is committed to making rare disease drugs available at the first sign of promise. Pharma tuck-in deals are increasing after a slow first quarter for small biotechs. BioAgc Biologics will be attending Bio International in Boston to discuss their global drug production capabilities.Stay tuned for more updates on investing in research, welcoming global talent, the biotech VC cycle, Gilead's challenge to J&J in the multiple myeloma CAR-T market, and much more. Upcoming events and job listings in the pharmaceutical industry are also featured in our newsletter.Thank you for tuning in to Pharma and Biotech daily.

Zach catches up on the three newest series to be released in the DC Absolute Universe!On the docket:Absolute Martian Manhunter #1-3 (DC Comics)Written by Deniz CampArt by Javier RodriguezLetters by Hassan Otsmane-ElhaouAbsolute Flash #1-3 (DC Comics)Written by Jeff LemireArt by Nick RoblesColors by Adriano LucasLetters by Tom NapolitanoAbsolute Green Lantern #1-2 (DC Comics)Written by Al EwingArt by Jahnoy LindsayLetters by Lucas Gattoni---------------------------------------------------Check out Dreampass and all their killer tracks on Spotify!---------------------------------------------------Join the Patreon to help us keep the lights on, and internet connected! https://www.patreon.com/tctwl---------------------------------------------------Listen to my other podcast!TFD: NerdcastAnd I am also part of the team over at...I Read Comic Books!---------------------------------------------------Want to try out all the sweet gigs over on Fiverr.com? Click on the link below and sign up!https://go.fiverr.com/visit/?bta=323533&brand=fiverrcpa---------------------------------------------------Follow on Instagram!The Comics That We LoveFollow on Tiktok!The Comics that We LoveFollow on Bluesky!comicsthatwelove.bsky.social

Let us know if there's a topic you'd like us to cover! Welcome back to Green Industry Perspectives! In this episode, Jay Worth welcomes Marie Ambusk to the show!A bad experience with a landscaper set Marie on a nearly two-decade journey to make things right. When the street trees in her neighborhood failed after less than 20 years, she asked the landscape company replacing them what happened. The answer, "You get what you get, lady," made her blood boil. Since then, she's not only become a Master Gardener. She's developed a way to determine if trees are going to fail. Those street trees had root collar disorder. Once she realized the problem lay in the containers and growing phase, she developed a way to inspect the root systems of containerized trees. Using ground-penetrating radar (GPR), AI, and machine-learning, she's been able to map and grade the root systems of container trees to predict failure with a stunning degree of accuracy. Phase II of her project will focus on using the same GPR technology to map defects in planted trees, saving many hours of labor in excavation to look for problems. In this episode, Marie shares why customer satisfaction, employee opportunities, and company growth and profit make the difference to your success in the Green Industry. For her, they all boil down to one core issue: establishing trust. ---Check Out the SingleOps Events Page!Check Out the LMN Events Page!---Visit the Trees ROI WebsiteConnect with Marie on LinkedInVisit the Trees ROI Facebook PageVisit the TREEage Vermont Facebook Page

Dutch biotech Merus' EGFR x LGR5 bispecific antibody has caught investors' attention in the run-up to ASCO as a new approach to block EGFR signaling. On the latest BioCentury This Week podcast, BioCentury's analysts discuss Phase II data from Merus for petosemtamab as they preview the American Society of Clinical Oncology's upcoming annual meeting. The analysts also assess a setback in a gene therapy trial for Rocket Pharmaceuticals, renewed interest in cancer target EpCAM, and a flurry of biopharma activity on the Hong Kong stock exchange. Finally, the team previews BioCentury's second annual Grand Rounds R&D meeting, which takes place next week in Chicago. This episode was sponsored by Jeito Capital.View full story: https://www.biocentury.com/article/656038#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment00:01 - Sponsor Message: Jeito Capital24:52 - HK IPOs07:12 - ASCO16:37 - EpCAM20:16 - RocketTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Robby Stanley and Paul Kuharsky, who is in for Rexrode the rest of the week, are talking all things Titans and NFL today.  What are some NFL headlines that are standing out early on?  The Titans are in Phase II of OTAs.  What do we think about how Callahan said the team is trying to address the mistakes from last season?  How much more sophisticated could the offense be this upcoming season?  Callahan gave an update on L'Jarius Sneed and his recovery from injury.

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Imlunestrant with or without abemaciclib in advanced breast cancer: Results of the Phase III EMBER-3 trial (0:00) Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract  Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the Phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1 and PTEN in HR-positive, HER2-negative metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (7:00) Bhave MA et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat 2024;207(3):599-609. Abstract Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), versus fulvestrant for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomized, Phase II trial (10:25) Oliveira M et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25(11):1424-39. Abstract Latest on SERDs: An education session at San Antonio Breast Cancer Symposium 2024 (13:57) Jeselsohn RM. Latest on selective estrogen receptor degraders (SERDs). San Antonio Breast Cancer Symposium 2024;Education Session 5. CME information and select publications

Phase II of the offseason program is underway in Tempe as the Arizona Cardinals rookies join the veterans for work. Craig Grialou, Paul Calvisi and former Cardinals QB Drew Stanton talk about building in the offseason, rookie CB Will Johnson's fit in Nick Rallis' defense, what kind of role we'll see from OLB Jordan Burch and if a push to start is realistic for sixth-round guard Hayden Conner out of Texas.See omnystudio.com/listener for privacy information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Donald Trump has issued an executive order to expedite the timeline for building new facilities in the US while increasing inspections on foreign plants. Despite a drop in venture capital fundraising in the first quarter of the year, large investments are still being made in the pharmaceutical industry. Companies like BMS are investing billions in US manufacturing despite potential tariffs. Vertex has seen success with their non-opioid pain drug launch and biopharma venture capital fundraising has declined, but median deal sizes remain high. Lotte Biologics offers specialized ADC manufacturing services in Syracuse, NY. Other news includes Lilly's ALS pipeline expansion, states suing to block HHS cuts, and layoffs at PTC despite a Phase II win. Thank you for tuning in to today's episode of Pharma and Biotech daily. Let's dive into the latest updates from the industry.

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dimitrios Goundis, CEO of Kither Biotech. Kither is a Phase I, soon to be Phase II, Italian biotech focused on respiratory diseases such as cystic fibrosis. This episode explores how emerging biotech strategies are advancing treatments for respiratory diseases like cystic fibrosis, with a focus on targeted drug delivery, clinical trial progression, and the evolving biotech landscape in Europe. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

  Lyssa Rome is a speech-language pathologist in the San Francisco Bay Area. She is on staff at the Aphasia Center of California, where she facilitates groups for people with aphasia and their care partners. She owns an LPAA-focused private practice and specializes in working with people with aphasia, dysarthria, and other neurogenic conditions. She has worked in acute hospital, skilled nursing, and continuum of care settings. Prior to becoming an SLP, Lyssa was a public radio journalist, editor, and podcast producer. In this episode, Lyssa Rome interviews Dr. Suma Devanga about collaborative referencing, gesture, and building rich communicative environments for people with aphasia.   Guest info Dr. Suma Devanga is an assistant professor in the Department of Communication Disorders and Sciences at Rush University Medical Center, Chicago, where she also serves as the director of the Aphasia Research Lab. She completed her PhD in Speech and Hearing science from the University of Illinois. Urbana Champaign in 2017. Dr. Devanga is interested in studying aphasia interventions and their impacts on people's everyday communication. Her recent work includes investigating a novel treatment called the Collaborative Referencing Intervention for Individuals with aphasia, using discourse analysis methods and patient reported outcome measures, studying group-based treatments for aphasia, and studying the use of gestures in aphasia. Additionally, she is involved in teaching courses on aphasia and cognitive communication disorders to graduate SLP students at Rush. She also provides direct patient care and graduate clinical supervision at Rush outpatient clinics.   Listener Take-aways In today's episode you will: Understand the role of collaborative referencing in everyday communication. Learn about Collaborative Referencing Intervention. Describe how speech-language pathologists can create rich communicative environments.   Edited transcript   Lyssa Rome Welcome to the Aphasia Access Aphasia Conversations Podcast. I'm Lyssa Rome. I'm a speech language pathologist on staff at the Aphasia Center of California, and I see clients with aphasia and other neurogenic communication disorders in my LPAA-focused private practice. I'm also a member of the Aphasia Access podcast Working Group. Aphasia Access strives to provide members with information, inspiration, and ideas that support their aphasia care through a variety of educational materials and resources.   I'm today's host for an episode that will feature Dr. Suma Devanga, who is selected as a 2024 Tavistock Trust for Aphasia Distinguished Scholar, USA and Canada. In this episode, we'll be discussing Dr. Devanga's research on collaborative referencing, gesture, and building rich communicative environments for people with aphasia.   Suma Devanga is an assistant professor in the Department of Communication Disorders and Sciences at Rush University Medical Center, Chicago, where she also serves as the director of the Aphasia Research Lab. She completed her PhD in Speech and Hearing science from the University of Illinois. Urbana Champaign in 2017. Dr. Devanga is interested in studying aphasia interventions and their impacts on people's everyday communication. Her recent work includes investigating a novel treatment called the Collaborative Referencing Intervention for Individuals with aphasia, using discourse analysis methods and patient reported outcome measures, studying group-based treatments for aphasia, and studying the use of gestures in aphasia. Additionally, she is involved in teaching courses on aphasia and cognitive communication disorders to graduate SLP students at Rush. She also provides direct patient care and graduate clinical supervision at Rush outpatient clinics. Suma Devanga, thank you so much for joining us today. I'm really happy to be talking with you.   Suma Devanga Thank you, Lyssa, thank you for having me. And I would also like to thank Aphasia Access for this wonderful opportunity, and the Tavistock Trust for Aphasia and the Duchess of Bedford for recognizing my research through the Distinguished Scholar Award.   Lyssa Rome So I wanted to start by asking you how you became interested in aphasia treatment.   Suma Devanga I became interested in aphasia during my undergraduate and graduate programs, which was in speech language pathology in Mysore in India. I was really drawn to this population because of how severe the consequences were for these individuals and their families after the onset of aphasia. So I met hundreds of patients and families with aphasia who were really devastated by this sudden condition, and they were typically left with no job and little means to communicate with family and friends. So as a student clinician, I was very, very motivated to help these individuals in therapy, but when I started implementing the treatment methods that I had learned, what I discovered was that my patients were showing improvements on the tasks that we worked on in therapy. Their scores on clinical tasks also were improving, but none of that really mattered to them. What they really wanted was to be able to easily communicate with family, but they continued to struggle on that, and none of the cutting-edge treatment methods that I learned from this highly reputable program in India were impacting my patients' lives.   So I really felt lost, and that is when I knew that I wanted to do a PhD and study this topic more closely, and I was drawn to Dr. Julie Hengst's work, which looked at the bigger picture in aphasia. She used novel theoretical frameworks and used discourse analysis methods for tracking patient performance, as opposed to clinical tests. So I applied to the University of Illinois PhD program, and I'm so glad that she took me on as her doctoral student. And so that is how I ended up moving from India to the US and started my work in aphasia.   Lyssa Rome I think that a lot of us can probably relate to what you're describing—that just that feeling of frustration when a patient might improve on some sort of clinical tasks, but still says this is not helping me in my life, and I know that for me, and I think for others, that is what has drawn us to the LPAA.   I wanted to sort of dive into your research by asking you a little bit more about rich communicative environments, and what you mean by that, and what you mean when you talk about or write about distributed communication frameworks.   Suma Devanga So since I started my PhD, I have been interested in understanding how we can positively impact everyday communication for our patients with aphasia. As a doctoral student, I delved more deeply into the aphasia literature and realized that what I observed clinically with my patients in India was consistent with what was documented in the literature, and that was called the clinical-functional gap. And this really refers to the fact that we have many evidence-based aphasia treatments that do show improvements on clinical tasks or standardized tests, but there is very limited evidence on these treatments improving the functional use of language or the everyday communication, and this remains to be true even today.   So I think it becomes pretty important to understand what we are dealing with, like what is everyday communication? And I think many aphasia treatments have been studying everyday communication or conversational interactions by decontextualizing them or reducing them into component parts, like single words or phrases, and then we work our way up to sentence structures. Right? So this approach has been criticized by some researchers like Clark, who is an experimental psychologist, and he called such tasks as in vacuo, meaning that they are not really capturing the complexity of conversational interactions. So basically, even though we are clinicians, our ultimate goal is improving everyday communication, which is rich and emergent and complex, we somehow seem to be using tasks that are simplified and that removes all of these complexities and focuses more on simple or specific linguistic structures. So to understand the complexities of everyday communication, we have shifted to the distributed communication framework, which really originates from the cultural historical activity theories and theories from linguistic anthropology.   Dr. Julie Hengst actually proposed the distributed communication theory in her article in the Journal of Communication Disorders in 2015, which highlights that communication is not just an individual skill or a discrete concept, but it is rather distributed. And it is distributed in three ways: One is that it is distributed across various resources. We communicate using multiple resources, not just language. We sign, we use gestures, or facial expressions. We also interpret messages using such resources like dialects and eye gaze and posture, the social context, cultural backgrounds, the emotional states that we are in, and all of that matters. And we all know this, right? This is not new, and yet, we often give credit to language alone for communication, when in reality, we constantly use multiple resources. And the other key concept of distributed communication theory is that communication is embedded in socio- cultural activities. So depending on the activity, which can be a routine family dinnertime conversation or managing relationships with your co workers, the communicative resources that you use, their motives, and the way you would organize it, all of that would vary. And finally, communication is distributed across time. And by that we mean that people interpret and understand present interactions through the histories that they have experienced over time. For example, if you're at work and your manager says you might want to double check your reports before submitting them based on prior interactions with the manager and the histories you've shared with them, you could interpret that message either as a simple suggestion or that there is a lack of trust in your work. So all in all, communication, I think, is a joint activity, and I think we should view it as a joint activity, and it depends on people's ability to build common ground with one another and draw from that common ground to interpret each other's messages.   Lyssa Rome I feel like that framework is really helpful, and it makes a lot of sense, especially as a way of thinking about the complexity of language and the complexity of what we're trying to do when we are taking a more top-down approach. So that's the distributed communication theory. And it sounds like the other framework that has really guided your research is rich communicative environments. And I'm wondering if you could say a little bit more about that.   Suma Devanga Absolutely. So this work originates from about 80 years of research in neuroscience, where rodents and other animals with acquired brain injuries showed greater neuroplastic changes and improved functions when they were housed in complex environments. In fact, complex environments are considered to be the most well replicated approach to improve function in animal models of acquired brain injury.   So Dr. Julie Hengst, Dr. Melissa Duff, and Dr. Theresa Jones translated these findings to support communication for humans with acquired brain injuries. And they called it the rich communicative environments. The main goal of this is to enrich the clinical environments. And how we achieve that is by ensuring that there is meaningful complexity in our clinical environments, and that you do that by ensuring that our patients, families, and clinicians use multimodal resources, and also to aim for having multiple communication partners within your sessions who can fluidly shift between various communicative roles, and to not just stay in that clinician role, for example.   Another way to think about enriching clinical environments is to think about ensuring that there is voluntary engagement from our patients, and you do that by essentially designing personally meaningful activities, rather than focusing on rehearsing fixed linguistic form or having some predetermined goals.   And the other piece of the enrichment is, how do we ensure there is a positive experiential quality for our patients within our sessions. And for this rather than using clinician-controlled activities with rigid interactional roles, providing opportunities for the patients to share stories and humor would really, you know, ensure that they are also engaging with the tasks with you and having some fun. So all of this put together would lead to a rich communicative environment.   Lyssa Rome It sounds like what you're describing is the kind of speech therapy environment and relationship that is very much person-centered and focused on natural communication, or natural communicative contexts and the kinds of conversations that people have in their everyday lives, rather than more sort of strict speech therapy protocol that might have been more traditional. I also want to ask you to describe collaborative referencing and collaborative referencing intervention.   Suma Devanga Yes, absolutely. So traditionally, our discipline has viewed word-finding or naming as a neurolinguistic process where you access semantic meanings from a lexicon, which you use to generate verbal references. And that theoretical account conceptualizes referencing as an isolated process, where one individual has the skill of retrieving target references from their stores of linguistic forms and meanings, right? So in contrast to that, the distributed communication perspective views referencing as a process where speakers' meanings are constructed within each interaction, and that is based on the shared histories of experiences with specific communication partners and also depending on the social and physical contexts of the interaction as well.   Now this process of collaborative referencing is something that we all do every single day. It is not just a part of our everyday communication, but without collaborative referencing, you cannot really have a conversation with anyone. You need to have some alignment, some common ground for communicating with others. This is a fundamental feature of human communication, and this is not new. You know, there is lots of work being done on this, even in childhood language literature as well.   Collaborative referencing was formally studied by Clark, who is the experimental psychologist. And he studied this in healthy college students, and he used a barrier task experiment for it. So a pair of students sat across from each other with a full barrier that separated them so they could not see each other at all, and each student had a board that was numbered one through 12, and they were given matching sets of 12 pictures of abstract shapes called tangrams. One participant was assigned as the director, who arranged the cards on their playing board and described their locations to the other, who served as the matcher and matched the pictures to their locations on their own board. So the pair completed six trials with alternating turns, and they use the same cards with new locations for each trial. And what they found was that the pairs had to really collaborate with each other to get those descriptions correct so that they are placed correctly on the boards.   So in the initial trials, the pairs had multiple turns of back and forth trying to describe these abstract shapes. For example, one of the pictures was initially described as “This picture that looks like an angel or something with its arms wide open.” And there had to be several clarifying questions from the partner, and then eventually, after playing with this picture several times, the player just had to say “It's the angel,” and the partner would be able to know which picture that was so as the pairs built their common ground, the collaborative effort, or the time taken to complete each trial, and the number of words they used and the number of turns they took to communicate about those pictures declined over time, and the labels itself, or the descriptions of pictures, also became more streamlined as the as time went by.   So Hengst and colleagues wanted to study this experiment in aphasia, TBI, amnesia, and Alzheimer's disease as well. So they adapted this task to better serve this population and also to align with the distributed communication framework. And surprisingly, they found consistent results that despite aphasia or other neurological conditions, people were still able to successfully reference, decrease collaborative effort over time and even streamline their references. But more surprisingly, people were engaged with one another. They were having really rich conversations about these pictures. They were sharing jokes, and really seemed to be enjoying the task itself.   So Hengst and colleagues realized that this has a lot of potential, and they redesigned the barrier task experiment as a clinical treatment using the principles of the distributed communication framework and the rich communicative environment. So that redesign included replacing the full barrier with a partial barrier to allow multimodal communication, and using personal photos of the patients instead of the abstract shapes to make it more engaging for the patients, and also asking participants to treat this as a friendly game and to have fun. So that is the referencing itself and the research on collaborative referencing, and that is how it was adapted as a treatment as well.   And in order to help clinicians easily implement this treatment, I have used the RTSS framework, which is the rehabilitation treatment specification system, to explain how CRI works and how it can be implemented. And this is actually published, and it just came out in the most recent issue in the American Journal of Speech Language Pathology, which I'm happy to share.   Lyssa Rome And we'll put that link into the show notes.   Suma Devanga Perfect. So CRI is designed around meaningful activities like the game that authentically provides repeated opportunities for the client and the clinician to engage in the collaborative referencing process around targets that they really want to be talking about, things that are relevant to patients, everyday communication goals, it could be things, objects of interest, and not really specific words or referencing forms.   So the implementation of the CRI involves three key ingredients. One is jointly developing the referencing targets and compiling the images so clinicians would sit down with the patients and the families to identify at least 30 targets that are meaningful and important to be included in the treatment. And we need two perspectives, or two views, or two pictures related to the same target that needs to be included in the treatment. So we will have 60 pictures overall. An example is two pictures from their wedding might be an important target for patients to be able to talk about. Two pictures from a Christmas party, you know, things like that. So this process of compilation of photos is also a part of the treatment itself, because it gives the patients an opportunity to engage with the targets.   The second ingredient is engaging in the friendly gameplay itself. And the key really here is the gameplay and to treat it as a gameplay. And this includes 15 sessions with six trials in each session, where you, as the clinician and the client will both have matching sets of 12 pictures, and there is a low barrier in between, so you cannot see each other's boards, but you can still see the other person. So you will both take turns being the director and the matcher six times, and describe and match the pictures to their locations, and that is just the game. The only rule of the game is that you cannot look over the barrier. You are encouraged to talk as much as you like about the pictures. In fact, you are encouraged to talk a lot about the pictures and communicate in any way.   The third ingredient is discussing and reflecting on referencing. And this happens at the end of each session where patients are asked to think back and reflect and say what the agreed upon label was for each card. And this, again, gives one more opportunity for the patients to engage with the target.   The therapeutic mechanism, or the mechanism of action, as RTSS likes to call it, is the rich communicative environment itself, you know, and how complex the task is, and how meaningful and engaging the task has to be, as well as the repeated engagement in the gameplay, because we are doing this six times in each session, and we are repeatedly engaging with those targets when describing them and placing them.   So what we are really targeting with CRI is collaborative referencing and again, this does not refer to the patient's abilities to access or retrieve those words from their stores. Instead, we are targeting people's joint efforts in communicating about these targets, their efforts in building situated common ground. That's what we are targeting. We are targeting their alignment with one another, and so that is how we define referencing. And again, we are targeting this, because that is how you communicate every day.   Lyssa Rome That sounds like a really fascinating and very rich intervention. And I'm wondering if you can tell us a little bit about the research that you've done on it so far.   Suma Devanga Absolutely. So in terms of research on CRI thus far, we have completed phase one with small case studies that were all successful, and my PhD dissertation was the first phase two study, where we introduced an experimental control by using a multiple-probe, single-case experimental design on four people with aphasia, and we found significant results on naming. And since then, I have completed two replication studies in a total of nine participants with aphasia. And we have found consistent results on naming. In terms of impact on everyday interactions, we have found decreased trouble sources, or communicative breakdowns, you can call it, and also decreased repairs, both of which indicated improved communicative success within conversational interactions. So we are positive, and we plan to continue this research to study its efficacy within a clinical trial.   Lyssa Rome That's very encouraging. So how can clinicians target collaborative referencing by creating a rich communicative environment?   Suma Devanga Yeah, well, CRI is one approach that clinicians can use, and I'm happy to share the evidence we have this far, and there is more to come, hopefully soon, including some clinical implementation studies that clinicians can use. But there are many other ways of creating rich communicative environments and targeting referencing within clinical sessions. I think many skilled clinicians are already doing it in the form of relationship building, by listening closely to their patients, engaging with them in authentic conversations, and also during education and counseling sessions as well.   In addition to that, I think group treatment for aphasia is another great opportunity for targeting collaborative referencing within a rich communicative environment. When I was a faculty at Western Michigan University, I was involved in their outpatient aphasia program, where they have aphasia groups, and patients got to select which groups they want to participate in. They had a cooking group, a music group, a technology group, and so on. And I'm guessing you do this too at the Aphasia Center of California. So these groups definitely create rich communicative environments, and people collaborate with each other and do a lot of referencing as well. So I think there is a lot that can be done if you understand the rich communicative environment piece.   Lyssa Rome Absolutely. That really rings true to me. So often in these podcast interviews, we ask people about aha moments, and I'm wondering if you have one that you wanted to share with us.   Suma Devanga Sure. So you know how I said that getting the pictures for the CRI is a joint activity? Patients typically select things that they really want to talk about, like their kids' graduation pictures, or things that they are really passionate about, like pictures of their sports cars, or vegetable gardens, and so on. And they also come up with really unique names for them as well, while they are playing with those pictures during the treatment. And when we start playing the game, clinicians usually have little knowledge about these images, because they're all really personal to the patients, and they're taken from their personal lives, so they end up being the novices, while the patients become the experts. And my patients have taught me so much about constructing a house and all about engines of cars and things like that that I had no knowledge about. But in one incident, when I was the clinician paired with an individual with anomic aphasia, there was a picture of a building that she could not recognize, and hence she could not tell me much at all. And we went back and forth several times, and we finally ended up calling it the “unknown building.” Later, I checked my notes and realized that it was where she worked, and it was probably a different angle, perhaps, which is why she could not recognize it. But even with that new information, we continue to call it the “unknown building,” because it became sort of an internal joke for us. And later I kept thinking if I had made a mistake and if we should have accurately labeled it. That is when it clicked for me that CRI is not about producing accurate labels, it is about building a common ground with each other, which would help you successfully communicate with that person. So you're targeting the process of referencing and not the reference itself, because you want your patients to get better at the process of referencing in their everyday communication. And so that was my aha moment.   Lyssa Rome Yeah, that's an amazing story, because I think that that gets to that question sort of of the why behind what we're doing, right? Is it to say the specific name? I mean, obviously for some people, yes, sometimes it is. But what is underlying that? It's to be able to communicate about the things that are important to people. I also wanted to ask you about another area that you've studied, which is the use of gesture within aphasia interventions. Can you tell us a little bit more about that?   Suma Devanga Yes. So this work started with my collaboration with my friend and colleague, Dr. Mili Mathew, who is at Molloy University in New York, and our first work was on examining the role of hand gestures in collaborative referencing in a participant who had severe Wernicke's aphasia, and he frequently used extensive gestures to communicate. So when he started with CRI his descriptions of the images were truly multimodal. For example, when he had to describe a picture of a family vacation in Cancun, he was, you know, he was verbose, and there was very little meaningful content that was relevant in his spoken language utterances. But he used a variety of iconic hand gestures that were very meaningful and helpful to identify what he was referring to. As the sessions went on with him, his gestural references also became streamlined, just like the verbal references do, and that we saw in other studies. And that was fascinating because it indicated that gestures do play a big role in the meaning-making process of referencing.   And in another study on the same participant, we explored the use of hand gestures as treatment outcome measures. This time, we specifically analyzed gestures used within conversations at baseline treatment, probe, and maintenance phases of the study. And we found that the frequency of referential gestures, which are gestures that add meaning, that have some kind of iconics associated with them, those frequencies of gestures decreased with the onset of treatment, whereas the correct information units, or CIUS, which indicate the informativeness in the spoken language itself, increased. So this pattern of decrease in hand gestures and increase in CIUS was also a great finding. Even though this was just an exploratory study, it indicates that gestures may be included as outcome measures, in addition to verbal measures, which we usually tend to rely more on. And we have a few more studies coming up that are looking at the synchrony of gestures with spoken language in aphasia, but I think we still have a lot more to learn about gestures in aphasia.   Lyssa Rome It seems like there that studying gestures really ties in to CRI and the rich communicative environments that you were describing earlier, where the goal is not just to verbally name one thing, but rather to get your point across, where, obviously, gesture is also quite useful. So I look forward to reading more of your research on that as it comes out. Tell us about what you're currently working on, what's coming next.   Suma Devanga Currently, I am wrapping up my clinical research grant from the ASH Foundation, which was a replication study of the phase two CRI so we collected data from six participants with chronic aphasia using a multiple-probe, single-case design, and that showed positive results on naming, and there was improved scores on patient reports of communication confidence, communicative participation, and quality of life as well. We are currently analyzing the conversation samples to study the treatment effects.   I also just submitted a grant proposal to extend the study on participants with different severities of aphasia as well. So we are getting all the preliminary data at this point that we need to be able to start a clinical trial, which will be my next step.   So apart from that, I was also able to redesign the CRI and adapt it as a group-based treatment with three participants with aphasia and one clinician in a group. I actually completed a feasibility study of it, which was successful, and I presented that at ASHA in 2023. And I'm currently writing it up for publication, and I also just secured an internal grant to launch a pilot study of the group CRI to investigate the effects of group CRI on communication and quality of life.   Lyssa Rome Well, that's really exciting. And again, I'm really looking forward to reading additional work as it comes out. As we wrap up. What do you want clinicians to take away from your work and to take away from this conversation we've had today?   Suma Devanga Well, I would want clinicians to reflect on how their sessions are going and think about how to incorporate the principles of rich communicative environments so that they can add more meaningful complexity to their treatment activities and also ensure that their patients are truly engaging with the tasks and also having some fun. And I would also tell the clinicians that we have strong findings so far on CRI with both fluent and non-fluent aphasia types. So please stay tuned and reach out to me if you have questions or want to share your experiences about implementing this with your own patients, because I would love to hear that.   Lyssa Rome Dr. Suma Devanga, it has been great talking to you and hearing about your work. Thank you so much for sharing it with us.   Suma Devanga It was fantastic talking about my work. Thank you for giving me this platform to share my work with you all. And thank you, Lyssa for being a great listener.   Lyssa Rome Thanks also to our listeners for the references and resources mentioned in today's show. Please see our show notes. They're available on our website, www.aphasiaaccess.org. There, you can also become a member of our organization, browse our growing library of materials, and find out about the Aphasia Access Academy. If you have an idea for a future podcast episode, email us at info@aphasiaaccess.org. Thanks again for your ongoing support of aphasia. Access. For Aphasia Access Conversations. I'm Lyssa Rome.       References   Devanga, S. R. (2025). Collaborative Referencing Intervention (CRI) in Aphasia: A replication and extension of the Phase II efficacy study. American Journal of Speech-Language Pathology. Advance online publication. https://doi.org/10.1044/2024_AJSLP-24-00226   Devanga, S. R., Sherrill, M., & Hengst, J. A. (2021). The efficacy of collaborative referencing intervention in chronic aphasia: A mixed methods study. American Journal of Speech Language Pathology, 30(1S), 407-424. https://doi.org/10.1044/2020_AJSLP-19-00108    Hengst, J. A., Duff, M. C., & Jones, T. A. (2019). Enriching communicative environments: Leveraging advances in neuroplasticity for improving outcomes in neurogenic communication disorders. American Journal of Speech-Language Pathology, 28(1S), 216–229. https://doi.org/10.1044/2018_AJSLP-17-0157   Hengst, J. A. (2015). Distributed communication: Implications of cultural-historical activity theory (CHAT) for communication disorders. Journal of Communication Disorders, 57, 16–28. Https://doi.org/10.1016/j.jcomdis.2015.09.001   Devanga, S. R., & Mathew, M. (2024). Exploring the use of co-speech hand gestures as treatment outcome measures for aphasia. Aphasiology. Advanced online publication. https://doi.org/10.1080/02687038.2024.2356287   Devanga, S. R., Wilgenhof, R., & Mathew, M. (2022). Collaborative referencing using hand gestures in Wernicke's aphasia: Discourse analysis of a case study. Aphasiology, 36(9), 1072-1095. https://doi.org/10.1080/02687038.2021.1937919    

Can a glass of pomegranate juice really help slow the growth of prostate cancer? In this episode of The Moss Report, Ben Moss and Dr. Ralph W. Moss take a deep dive into the clinical research on pomegranate and cancer—especially prostate cancer. They explore landmark studies from Johns Hopkins and UCLA, uncover the political backstory behind the POMx extract, and offer practical guidance for integrating pomegranate into a cancer-fighting or preventative diet. Dr. Moss also shares his personal use of pomegranate powder, discusses antioxidant synergy, and introduces options that reduce sugar intake without sacrificing benefits. A compelling look at how traditional foods meet cutting-edge science. “Fill up that self-help space with scientifically documented ways to reduce your cancer risk.” – Dr. Ralph W. Moss

In this episode of The Scope of Things, host Deborah Borfitz covers the latest news, including setting expectations for Phase II cancer trials, key learnings about dementia from the Nun Study, links between cardiovascular disease and mild cognitive impairment, using aspirin to prevent cancer spread, a clinical trial map to improve study access, and a naturally occurring molecule that rivals Ozempic in its weight loss potential. Deborah also speaks with Ravi Parikh, medical director of data and technology applications shared resource at Winship Cancer Institute of Emory University, about a novel AI platform he helped develop to translate clinical trial results to real world populations. News Roundup Phase 2 cancer drug trials Study in the Journal of the National Cancer Institute   Nun Study insights Review article in Alzheimer's & Dementia  DORIAN GRAY project Press release by the European Society of Cardiology Aspirin for preventing cancer spread Study in Nature  New clinical trial map  News announcement on the EMA website Molecule rivaling Ozempic Study in NatureThe Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

Jamie is a 62-year-old female who is referred to outpatient cardiac rehabilitation 3 weeks after a myocardial infarction. She reports feeling fatigued with moderate exertion but denies chest pain. Her resting vitals are HR 80 bpm, BP 128/82 mmHg, and SpO₂ 98%. She completed Phase I rehabilitation without complications and is eager to begin exercising to improve her endurance. Which activity is MOST appropriate to initiate during Phase II of cardiac rehabilitation?A) Jogging on a treadmill at 70% maximum heart ratB) Cycling on a stationary bike at 3-5 METsC) Strength training at 50% of 1-rep maxD) Stretching and light walking onlyDOWNLOAD THIS EPISODES CHEATSHEET:www.nptecheatsheet.com/cardiac-rehab1

It's public space night, and the wide ranging group discussion ensues. Grant joins Tore for the evening. Bringing people along slowly takes a strategy. Credible information can be fed to soft prime the world. It's disclosure, but a gentle one. Thru whistle blowers works great. We are actually in Phase II. There's more than one Arc Of The Covenant. Science created one version. Huh? Planet X could raise gravitational havoc. Why would NASA be hinting? Poles have flipped before, but we didn't depend on tech back then. Another Y2K? Pyramids exist all over the world. Advanced ancient tech is a good bait subject. Tesla terrorists could be planted. Bergrum and the contract tracing app. What did Jesus study in the unknown years. Was alchemy on the list? Religion as a whip has been very effective. When two or more gather, that's a church. They hijacked all religions, not just Christianity. How important is your faith to you? Dialing God's number outside the space. Focusing on life's purpose, which is service to others. And, it's reciprocal. The essence of the Koran is actually love. The big question remains, is free will there too? Going to bliss without Netflix. The pyramids might be at the epicenter of what's to come. Love yourself and God, then the rest will come naturally.

Sulfurophane and health - It is clear now that SFN stands out as a powerhouse phytochemical with profound effects on human health through the pathway of nurclear factor erythroid related 2 (NRF2). It is found abundantly in cruciferous vegetables such as broccoli, broccolini, kale, and brussels sprouts. SFN is a bioactive compound with impressive clinical potential for preventing chronic disease and optimizing cellular health, especially in oxidant impaired/overloaded states. At its core, SFN is a sulfur-rich molecule derived from glucoraphanin, a glucosinolate precursor. The transformation occurs when the enzyme myrosinase, released during the chopping or chewing of cruciferous vegetables, catalyzes the reaction. Interestingly, this enzymatic activation can also be achieved via gut microbiota when raw vegetables are absent from the diet, emphasizing the remarkable adaptability of our biology to source essential nutrients as needed for survival. (Ali et. al. 2023) Nrf2 is a master regulator of cellular defense, orchestrating the production of detoxification enzymes, antioxidants, and other cytoprotective proteins. By activating Nrf2, sulforaphane enhances the body's resilience to oxidative stress, a key contributor to aging, inflammation, and the development of chronic diseases such as cardiovascular disease and diabetes. Studies reveal that sulforaphane also induces Phase II detoxification enzymes, such as glutathione S-transferase, which play a vital role in neutralizing and excreting harmful toxins.

A JAMA study identified factors linked to loss to follow-up in diabetic retinopathy and macular edema patients, including male gender, distance from care, and sociodemographic disparities. In Vietnam, six months of levofloxacin therapy showed a non-significant reduction in multidrug-resistant tuberculosis, emphasizing the balance between benefits and tolerability. Finally, Phase II trial showed pancigromab's promise in addressing cancer cachexia, with weight gain and symptom improvement, supporting further research.

HEALTH NEWS   ·         Mediterranean plants show promise for cardiovascular disease treatment ·         Walking away from depression: How daily steps improve mental health ·         Phase II trial finds fish oil reduces prostate cancer progression in men undergoing active surveillance  ·         Hot tub therapy offers hope for people with type 2 diabetes ·          Study: Sugary Drinks Increase Risk of Endometrial Cancer in Women ·         Transcendental Meditation most effective at treating PTSD in largest review to date 

KB is BACK and kicks things off celebrating another Victory Monday for the Eagles as they take down the Rams in LA on Sunday Night Football. He discusses Saquon Barkley's UNREAL and historic performance that helped propel the team to victory. He also discusses the unfortunate news that Brandon Graham tore his triceps and is out for the remainder of the season. KB discusses BG and his importance to the franchise and why the Eagles gotta go and win it all for BG now. Then he discusses the Sixers continuing to stink, the Flyers grinding out a win this weekend against Chicago and Matvei Michkov is unreal. He also touches on Juan Soto SZN advancing to Phase II and gives some fun news happening this week at Underground! GO BIRDS! Onboarding Form: forms.gle/mZYnkiQcGv1ZxBSg9 Voicemail Line: speakpipe.com/UndergroundSportsPhiladelphia Support Our Sponsors! The City of Vineland: Visit www.vinelandcity.org/ and stay connected with the community and learn about important announcements, programs, and services offered by the city! Vineland, New Jersey... Where It's Always Growing Season! '47 Brand Shop for your favorite sports fan and get 30% off SITE WIDE from Black Friday through Cyber Monday and get FREE SHIPPING on ALL orders with '47 Brand! 47.sjv.io/GmAQ2k Kenwood Beer Visit kenwoodbeer.com/#finder to see who has Kenwood Beer on tap in your area! (MUST be 21+ to do so and PLEASE drink responsibly.) Paramount+ Sign up for Paramount+ and stream the NFL all season long! https://paramountplus.qflm.net/c/2698521/2140293/3065 FOCO Shop the new, officially licensed 76ers merchandise & collectibles from FOCO! linktr.ee/undergroundsportspartnerships Merch & Apparel: www.phiapparel.co/shop + Use Code "UNDERGROUND" for 10% off! Duracell Portable Power Stations For a limited time - Take 35% off Sitewide Plus Free Shipping. Use code CYBER35 linktr.ee/undergroundsportspartnerships Tomahawk Shades Take 25% off your next order with code USP at tomahawkshades.com or in the Tomahawk Shades App! Follow Us! Twitter: twitter.com/UndergroundPHI Instagram: www.instagram.com/undergroundphi/ TikTok: tiktok.com/@undergroundphi KB: twitter.com/KBizzl311 Watch LIVE: YouTube: www.youtube.com/@UndergroundSportsPhiladelphia FB: facebook.com/UndergroundSportsPHI Twitch: twitch.tv/UndergroundsportsPHI Intro Music: Arkells "People's Champ" Outro Music: Arkells "People's Champ" #subscribe #Eagles #FlyEaglesFly #Phillies #Sixers #Flyers #fyp

Watch The X22 Report On Video No videos found Click On Picture To See Larger PictureMore and more banks are being investigated for money laundering, they said criminals only use bitcoin for money laundering. US economy grew because of gov spending and inflation. Fed cuts rates mortgage rates climb higher. As the economy implodes gold and bitcoin will skyrocket. The [DS] is trying everything they can to manipulate the election using ballots. The problem is that the people continue to catch them cheating, which is making hard for the [DS]. Dominion machines have been affected nationwide and might not produce the right results. The honeypot that Comey used on Trump has been exposed. The [DS] is panicking, its all falling apart on them.   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Economy BofA Warns "Enforcement Action" By Feds Possible Over Money Laundering, Zelle  A little more than two weeks after Toronto-Dominion Bank pleaded guilty to multiple criminal charges and paid $3 billion in fines and other penalties to the Department of Justice and financial regulators for failing to monitor money laundering operatio  the Corporation's Bank Secrecy Act/anti-money laundering and sanctions compliance programs (Programs), including transaction monitoring, training, governance, and customer due diligence."  "In cooperation with regulators, the Corporation has been, and plans to continue, implementing enhancements to these Programs. The Corporation is continuing discussions with its regulators about the Programs, and resolution of these discussions may include one or more public orders by the regulators," BofA continued. BofA is responding to an inquiry from the Consumer Financial Protection Bureau into electronic payments on the Zelle payment network. "The CFPB staff has initiated discussions with the Corporation to pursue a resolution of the inquiry or file an enforcement action. The Corporation is evaluating next steps, including litigation," the bank said. The filing did not mention specifics about potential AML issues. However, the TD Bank case, where the Canadian bank chose profits over AML compliance, allowed fentanyl and narcotics trafficking operations to use banking services. Source: zerohedge.com U.S. Economy Grew At 2.8% Pace In Third Quarter The U.S. economy expanded at a 2.8 percent annual pace in the third quarter, the Commerce Department said Wednesday. Consumer spending jumped  3.7 percent in the third quarter, the largest rise in six quarters. That was much higher than the three percent expected. Imports, which are a subtraction from GDP, soared in the third quarter. Imports of goods climbed 11.6 percent, partially reflecting U.S. importers pulling forward imports for fear that the port worker strike would be a lasting obstacle to bringing in foreign-made products. This dragged down GDP by nine-tenths of a percentage point. Government spending was a big source of economic growth in the quarter, adding nine-tenths of a percentage point to GDP growth. Source: breitbart.com https://twitter.com/KobeissiLetter/status/1851291535683318037  for $420,400 which means a mortgage payment with 20% down would be $2,343/month. Including taxes and insurance, homebuyers can now expect to spend over $3,000/month. In other words, homebuyers are now spending over 50% of their post-tax income on home payments. Truly mind-blowing numbers. https://twitter.com/KobeissiLetter/status/1851659293059141954    $3,000 monthly budget can now afford a $442,500 home, down from $475,750 on September 17th, the lowest since February 2023. A homebuyer with a $2,

Watch The X22 Report On Video No videos found Click On Picture To See Larger PictureThe oil companies are now shifting away from the green agenda, they are realizing that if they continue down this path they will go bankrupt. [KH] plan is the same plan the [DS] has been pushing, tax the rich. Gold bars at Costco are flying off the shelf, why would that be if the economy is strong. The [DS] is in trouble, [KH] fake poll numbers are imploding, they will not have the poll numbers to create the ballots they need. [DS] ready to shift into Phase II of the election rigging. They need to give [KH] a boost or they need to swap her out. The [DS] ready to move into phase II which is post election. The stage has been set and now the [DS] is going down the path the patriots have set for them.   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Economy Energy Giant Puts Goal To Drastically Cut Oil, Gas Production On Ice European energy company BP has abandoned its pledge to cut oil and gas production by 2030 as the firm aims to shore up investor confidence amid a slide in its share price, Reuters reported Monday. BP unveiled plans in August 2020 to reduce its oil and gas output 40% by 2030, before dialing back the target to 25% in February 2023, according to Reuters. Now, in an attempt to regain the trust of investors, CEO Murray Auchincloss has dropped the target altogether in what sources told Reuters is part of a broader corporate strategy shift to focus on profitability and returns rather than green initiatives The news follows BP announcing plans to sell its roughly $2 billion U.S. onshore wind portfolio in September and comes as the company's share price sits at a near two-year low. It also coincides with a strategy shift at rival energy company Shell, which rejected further cuts to oil production in June 2023 shortly before its CEO Wael Sawan described lowering oil output as “dangerous and irresponsible” in a July 2023 interview with the BBC. Source: dailycaller.com https://twitter.com/Bubblebathgirl/status/1843275996008714598 TAKE A LISTEN https://twitter.com/GRDecter/status/1843303350751949214   https://twitter.com/KobeissiLetter/status/1843306086532788267 https://twitter.com/GRDecter/status/1843266608392732990   Political/Rights https://twitter.com/TheStormRedux/status/1843261819814592887 having a hard time telling the difference between fact and fiction, is creating an impedance to our ability to actually get people the help they need.” She's talking about President Trump, btw. Oh and then Morning Joe chimes in and suggests it could be “foreign powers” Man, these people are toast. https://twitter.com/ThomTillis/status/1843302920084976027   FEMA Abandons Devastated NC Town Residents — ‘Nobody's Been Bringing in Supplies Except Civilians' After Agency Refuses to Drive Around ‘Road Closed' Sign    Chelsea Atkins, 38, a health researcher originally from Buffalo, NY, shared her frustration with FEMA's incompetence in an interview with the New York Post. “FEMA called me and told me they wanted to inspect my house, then called me back to say they couldn't drive around the ‘road closed' sign. They weren't allowed,” she told The Post. “You can drive it by car for sure, it's not that bad, you just have to drive around the ‘road closed' sign. I explained that to them. They said they couldn't.” Take note that it is the very same road The Post successfully traversed on its way to Bat Cave. “FEMA hasn't been here,” Atkins said, adding, “It's been a civilian-run operation since day one.